Health  ||| S:0 E:7 ||| NNP
economic  ||| S:7 E:16 ||| JJ
evaluation  ||| S:16 E:27 ||| NN
of  ||| S:27 E:30 ||| IN
outpatient  ||| S:30 E:41 ||| JJ
management  ||| S:41 E:52 ||| NN
of  ||| S:52 E:55 ||| IN
fibromyalgia  ||| S:55 E:68 ||| JJ
patients  ||| S:68 E:77 ||| NNS
and  ||| S:77 E:81 ||| CC
the  ||| S:81 E:85 ||| DT
costs  ||| S:85 E:91 ||| NNS
avoided  ||| S:91 E:99 ||| VBN
by  ||| S:99 E:102 ||| IN
diagnosing  ||| S:102 E:113 ||| JJ
fibromyalgia  ||| S:113 E:126 ||| NN
in  ||| S:126 E:129 ||| IN
France  ||| S:129 E:136 ||| NNP
To  ||| S:136 E:139 ||| TO
assess  ||| S:139 E:146 ||| VB
whether  ||| S:146 E:154 ||| IN
the  ||| S:154 E:158 ||| DT
decrease  ||| S:158 E:167 ||| NN
in  ||| S:167 E:170 ||| IN
medical  ||| S:170 E:178 ||| JJ
resource  ||| S:178 E:187 ||| NN
use  ||| S:187 E:191 ||| NN
and  ||| S:191 E:195 ||| CC
cost  ||| S:195 E:200 ||| NN
after  ||| S:200 E:206 ||| IN
diagnosing  ||| S:206 E:217 ||| JJ
fibromyalgia ||| S:217 E:229 ||| NN
,  ||| S:229 E:231 ||| ,
observed  ||| S:231 E:240 ||| VBD
in  ||| S:240 E:243 ||| IN
a  ||| S:243 E:245 ||| DT
large  ||| S:245 E:251 ||| JJ
primary  ||| S:251 E:259 ||| JJ
care  ||| S:259 E:264 ||| NN
population  ||| S:264 E:275 ||| NN
in  ||| S:275 E:278 ||| IN
the  ||| S:278 E:282 ||| DT
United  ||| S:282 E:289 ||| NNP
Kingdom  ||| S:289 E:297 ||| NNP
can  ||| S:297 E:301 ||| MD
be  ||| S:301 E:304 ||| VB
extrapolated  ||| S:304 E:317 ||| VBN
to  ||| S:317 E:320 ||| TO
France ||| S:320 E:326 ||| NNP
.  ||| S:326 E:328 ||| .
A  ||| S:328 E:330 ||| DT
questionnaire  ||| S:330 E:344 ||| NN
was  ||| S:344 E:348 ||| VBD
created  ||| S:348 E:356 ||| VBN
based  ||| S:356 E:362 ||| VBN
on  ||| S:362 E:365 ||| IN
medical  ||| S:365 E:373 ||| JJ
resource  ||| S:373 E:382 ||| NN
use  ||| S:382 E:386 ||| NN
by  ||| S:386 E:389 ||| IN
2,260  ||| S:389 E:395 ||| CD
patients  ||| S:395 E:404 ||| NNS
diagnosed  ||| S:404 E:414 ||| VBN
with  ||| S:414 E:419 ||| IN
fibromyalgia  ||| S:419 E:432 ||| NN
between  ||| S:432 E:440 ||| IN
01 ||| S:440 E:442 ||| CD
/ ||| S:442 E:443 ||| CD
01 ||| S:443 E:445 ||| CD
/ ||| S:445 E:446 ||| CD
1998  ||| S:446 E:451 ||| CD
and  ||| S:451 E:455 ||| CC
31 ||| S:455 E:457 ||| CD
/ ||| S:457 E:458 ||| CD
03 ||| S:458 E:460 ||| CD
/ ||| S:460 E:461 ||| CD
2003  ||| S:461 E:466 ||| CD
in  ||| S:466 E:469 ||| IN
the  ||| S:469 E:473 ||| DT
General  ||| S:473 E:481 ||| NNP
Practice  ||| S:481 E:490 ||| NNP
Research  ||| S:490 E:499 ||| NNP
Database  ||| S:499 E:508 ||| NNP
in  ||| S:508 E:511 ||| IN
the  ||| S:511 E:515 ||| DT
UK ||| S:515 E:517 ||| NNP
.  ||| S:517 E:519 ||| .
Sixty  ||| S:519 E:525 ||| JJ
French  ||| S:525 E:532 ||| JJ
experts  ||| S:532 E:540 ||| NNS
( ||| S:540 E:541 ||| -LRB-
general  ||| S:541 E:549 ||| JJ
practitioners ||| S:549 E:562 ||| NNS
,  ||| S:562 E:564 ||| ,
rheumatologists ||| S:564 E:579 ||| CD
)  ||| S:579 E:581 ||| -RRB-
assessed  ||| S:581 E:590 ||| VBN
whether  ||| S:590 E:598 ||| IN
the  ||| S:598 E:602 ||| DT
data  ||| S:602 E:607 ||| NNS
from  ||| S:607 E:612 ||| IN
that  ||| S:612 E:617 ||| DT
database  ||| S:617 E:626 ||| NN
are  ||| S:626 E:630 ||| VBP
in  ||| S:630 E:633 ||| IN
line  ||| S:633 E:638 ||| NN
with  ||| S:638 E:643 ||| IN
their  ||| S:643 E:649 ||| PRP$
clinical  ||| S:649 E:658 ||| JJ
practice  ||| S:658 E:667 ||| NN
and ||| S:667 E:670 ||| CC
,  ||| S:670 E:672 ||| ,
if  ||| S:672 E:675 ||| IN
not ||| S:675 E:678 ||| RB
,  ||| S:678 E:680 ||| ,
were  ||| S:680 E:685 ||| VBD
asked  ||| S:685 E:691 ||| VBN
to  ||| S:691 E:694 ||| TO
provide  ||| S:694 E:702 ||| VB
data  ||| S:702 E:707 ||| NNS
reflecting  ||| S:707 E:718 ||| VBG
their  ||| S:718 E:724 ||| PRP$
own  ||| S:724 E:728 ||| JJ
experience ||| S:728 E:738 ||| NN
.  ||| S:738 E:740 ||| .
The  ||| S:740 E:744 ||| DT
evaluation  ||| S:744 E:755 ||| NN
period  ||| S:755 E:762 ||| NN
went  ||| S:762 E:767 ||| VBD
from  ||| S:767 E:772 ||| IN
4  ||| S:772 E:774 ||| CD
years  ||| S:774 E:780 ||| NNS
before  ||| S:780 E:787 ||| IN
to  ||| S:787 E:790 ||| TO
4  ||| S:790 E:792 ||| CD
years  ||| S:792 E:798 ||| NNS
after  ||| S:798 E:804 ||| IN
diagnosis  ||| S:804 E:814 ||| NN
using  ||| S:814 E:820 ||| VBG
1-year  ||| S:820 E:827 ||| NNP
cross-sections ||| S:827 E:841 ||| NNP
.  ||| S:841 E:843 ||| .
Evaluated  ||| S:843 E:853 ||| JJ
resources  ||| S:853 E:863 ||| NNS
were  ||| S:863 E:868 ||| VBD
drug  ||| S:868 E:873 ||| NN
use ||| S:873 E:876 ||| NN
,  ||| S:876 E:878 ||| ,
diagnostics  ||| S:878 E:890 ||| JJ
tests ||| S:890 E:895 ||| NNS
,  ||| S:895 E:897 ||| ,
general  ||| S:897 E:905 ||| JJ
practitioners  ||| S:905 E:919 ||| NNS
and  ||| S:919 E:923 ||| CC
specialist  ||| S:923 E:934 ||| NN
visits ||| S:934 E:940 ||| NNS
,  ||| S:940 E:942 ||| ,
and  ||| S:942 E:946 ||| CC
also  ||| S:946 E:951 ||| RB
paramedical  ||| S:951 E:963 ||| JJ
or  ||| S:963 E:966 ||| CC
alternative  ||| S:966 E:978 ||| JJ
treatments ||| S:978 E:988 ||| NNS
.  ||| S:988 E:990 ||| .
Data  ||| S:990 E:995 ||| NNS
regarding  ||| S:995 E:1005 ||| VBG
inpatient  ||| S:1005 E:1015 ||| JJ
care  ||| S:1015 E:1020 ||| NN
and  ||| S:1020 E:1024 ||| CC
productivity  ||| S:1024 E:1037 ||| NN
loss  ||| S:1037 E:1042 ||| NN
were  ||| S:1042 E:1047 ||| VBD
not  ||| S:1047 E:1051 ||| RB
collected ||| S:1051 E:1060 ||| VBN
.  ||| S:1060 E:1062 ||| .
Medical  ||| S:1062 E:1070 ||| JJ
resource  ||| S:1070 E:1079 ||| NN
use  ||| S:1079 E:1083 ||| NN
if  ||| S:1083 E:1086 ||| IN
no  ||| S:1086 E:1089 ||| DT
diagnosis  ||| S:1089 E:1099 ||| NN
had  ||| S:1099 E:1103 ||| VBD
been  ||| S:1103 E:1108 ||| VBN
established  ||| S:1108 E:1120 ||| VBN
was  ||| S:1120 E:1124 ||| VBD
estimated ||| S:1124 E:1133 ||| VBN
,  ||| S:1133 E:1135 ||| ,
so  ||| S:1135 E:1138 ||| RB
the  ||| S:1138 E:1142 ||| DT
impact  ||| S:1142 E:1149 ||| NN
of  ||| S:1149 E:1152 ||| IN
diagnosis  ||| S:1152 E:1162 ||| NN
could  ||| S:1162 E:1168 ||| MD
be  ||| S:1168 E:1171 ||| VB
evaluated ||| S:1171 E:1180 ||| VBN
.  ||| S:1180 E:1182 ||| .
Whereas  ||| S:1182 E:1190 ||| IN
costs  ||| S:1190 E:1196 ||| NNS
gradually  ||| S:1196 E:1206 ||| RB
increase  ||| S:1206 E:1215 ||| VB
before  ||| S:1215 E:1222 ||| IN
diagnosis ||| S:1222 E:1231 ||| NN
,  ||| S:1231 E:1233 ||| ,
stagnation  ||| S:1233 E:1244 ||| NN
in  ||| S:1244 E:1247 ||| IN
costs  ||| S:1247 E:1253 ||| NNS
occurs  ||| S:1253 E:1260 ||| VBZ
in  ||| S:1260 E:1263 ||| IN
the  ||| S:1263 E:1267 ||| DT
year  ||| S:1267 E:1272 ||| NN
after  ||| S:1272 E:1278 ||| IN
diagnosis ||| S:1278 E:1287 ||| NN
,  ||| S:1287 E:1289 ||| ,
followed  ||| S:1289 E:1298 ||| VBN
by  ||| S:1298 E:1301 ||| IN
a  ||| S:1301 E:1303 ||| DT
moderate  ||| S:1303 E:1312 ||| JJ
decrease  ||| S:1312 E:1321 ||| NN
afterwards ||| S:1321 E:1331 ||| RB
.  ||| S:1331 E:1333 ||| .
The  ||| S:1333 E:1337 ||| DT
same  ||| S:1337 E:1342 ||| JJ
trend  ||| S:1342 E:1348 ||| NN
was  ||| S:1348 E:1352 ||| VBD
observed  ||| S:1352 E:1361 ||| VBN
whether  ||| S:1361 E:1369 ||| IN
the  ||| S:1369 E:1373 ||| DT
panel  ||| S:1373 E:1379 ||| NN
consisted  ||| S:1379 E:1389 ||| VBD
of  ||| S:1389 E:1392 ||| IN
general  ||| S:1392 E:1400 ||| JJ
practitioners  ||| S:1400 E:1414 ||| NNS
or  ||| S:1414 E:1417 ||| CC
rheumatologists ||| S:1417 E:1432 ||| NN
.  ||| S:1432 E:1434 ||| .
The  ||| S:1434 E:1438 ||| DT
savings  ||| S:1438 E:1446 ||| NNS
made  ||| S:1446 E:1451 ||| VBN
as  ||| S:1451 E:1454 ||| IN
a  ||| S:1454 E:1456 ||| DT
result  ||| S:1456 E:1463 ||| NN
of  ||| S:1463 E:1466 ||| IN
fibromyalgia  ||| S:1466 E:1479 ||| JJ
diagnosis  ||| S:1479 E:1489 ||| NN
add  ||| S:1489 E:1493 ||| VB
up  ||| S:1493 E:1496 ||| RP
to  ||| S:1496 E:1499 ||| TO
126  ||| S:1499 E:1503 ||| CD
euros  ||| S:1503 E:1509 ||| NN
per  ||| S:1509 E:1513 ||| IN
patient  ||| S:1513 E:1521 ||| NN
per  ||| S:1521 E:1525 ||| IN
year  ||| S:1525 E:1530 ||| NN
for  ||| S:1530 E:1534 ||| IN
the  ||| S:1534 E:1538 ||| DT
health  ||| S:1538 E:1545 ||| NN
care  ||| S:1545 E:1550 ||| NN
payer ||| S:1550 E:1555 ||| NN
.  ||| S:1555 E:1557 ||| .
General  ||| S:1557 E:1565 ||| JJ
practitioner  ||| S:1565 E:1578 ||| NN
visits ||| S:1578 E:1584 ||| NNS
,  ||| S:1584 E:1586 ||| ,
diagnostic  ||| S:1586 E:1597 ||| JJ
tests  ||| S:1597 E:1603 ||| NNS
and  ||| S:1603 E:1607 ||| CC
drug  ||| S:1607 E:1612 ||| NN
use  ||| S:1612 E:1616 ||| NN
represent  ||| S:1616 E:1626 ||| VBP
respectively  ||| S:1626 E:1639 ||| RB
57 ||| S:1639 E:1641 ||| CD
% ||| S:1641 E:1642 ||| NN
,  ||| S:1642 E:1644 ||| ,
23 ||| S:1644 E:1646 ||| CD
%  ||| S:1646 E:1648 ||| NN
and  ||| S:1648 E:1652 ||| CC
12 ||| S:1652 E:1654 ||| CD
%  ||| S:1654 E:1656 ||| NN
of  ||| S:1656 E:1659 ||| IN
the  ||| S:1659 E:1663 ||| DT
savings ||| S:1663 E:1670 ||| NNS
.  ||| S:1670 E:1672 ||| .
Also  ||| S:1672 E:1677 ||| RB
in  ||| S:1677 E:1680 ||| IN
France ||| S:1680 E:1686 ||| NNP
,  ||| S:1686 E:1688 ||| ,
early  ||| S:1688 E:1694 ||| JJ
diagnosis  ||| S:1694 E:1704 ||| NN
of  ||| S:1704 E:1707 ||| IN
fibromyalgia  ||| S:1707 E:1720 ||| NN
leads  ||| S:1720 E:1726 ||| VBZ
to  ||| S:1726 E:1729 ||| TO
a  ||| S:1729 E:1731 ||| DT
decrease  ||| S:1731 E:1740 ||| NN
in  ||| S:1740 E:1743 ||| IN
resource  ||| S:1743 E:1752 ||| JJ
use  ||| S:1752 E:1756 ||| NN
and  ||| S:1756 E:1760 ||| CC
health  ||| S:1760 E:1767 ||| NN
care  ||| S:1767 E:1772 ||| NN
costs ||| S:1772 E:1777 ||| NNS
.  ||| S:1777 E:1779 ||| .
